

ALEXION PHARMACEUTICALS INC  
 Form 4  
 September 25, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Sinha Vikas  
  
 (Last) (First) (Middle)  
 C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE  
 (Street)  
 CHESHIRE, CT 06410  
 (City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 ALEXION PHARMACEUTICALS INC [ALXN]

3. Date of Earliest Transaction (Month/Day/Year)  
 09/24/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 SVP & Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock, par value \$.0001 per share	09/24/2007		S	1,600 <sup>(1)</sup>	D \$ 63.4	31,106	D
Common Stock, par value \$.0001 per share	09/24/2007		S	100 <sup>(1)</sup>	D \$ 63.26	31,006	D

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$\$.0001 per share	09/24/2007	S	200 <u>(1)</u>	D	\$ 63.18	30,806	D
Common Stock, par value \$\$.0001 per share	09/24/2007	S	57 <u>(1)</u>	D	\$ 63.11	30,749	D
Common Stock, par value \$\$.0001 per share	09/24/2007	S	200 <u>(1)</u>	D	\$ 63.09	30,549	D
Common Stock, par value \$\$.0001 per share	09/24/2007	S	777 <u>(1)</u>	D	\$ 63.05	29,772	D
Common Stock, par value \$\$.0001 per share	09/24/2007	S	1,100 <u>(1)</u>	D	\$ 63.04	28,672	D
Common Stock, par value \$\$.0001 per share	09/24/2007	S	100 <u>(1)</u>	D	\$ 63.03	28,572	D
Common Stock, par value \$\$.0001 per share	09/24/2007	S	23 <u>(1)</u>	D	\$ 63	28,549	D
Common Stock, par value \$\$.0001 per share	09/24/2007	S	5 <u>(1)</u>	D	\$ 65.87	28,544	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sinha Vikas C/O ALEXION PHARMACUETICALS, INC. 352 KNOTTER DRIVE CHESHIRE, CT 06410	X		SVP & Chief Financial Officer	

## Signatures

/s/ Vikas Sinha                      09/25/2007

\_\_Signature of                      Date  
Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This sale was made pursuant to a plan designed to comply with Rule 10b5-1. The sale was in an amount necessary to satisfy tax withholding obligations incurred on the trading day prior to a sale due to vesting of previously granted Restricted Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.